Buprenorphine as a safe alternative to methadone in a patient with acquired long QT syndrome: A case report

Netherlands Heart Journal

Volumn 21, Issue 5, 2013, Pages 249-252

  de Jong, I M ^a   de Ruiter, G S ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Buprenorphine; Long QT; Methadone; Torsades de pointes

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE;

ADULT; ARTICLE; BRADYCARDIA; CASE REPORT; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HEMATOMA; HUMAN; INTRAVENOUS DRUG ABUSE; LONG QT SYNDROME; MALE; QT INTERVAL; TORSADE DES POINTES;

EID: 84877119602     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-011-0073-9     Document Type: Article

References (6)

1. Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation. 1999;99(4):518-28.
2. Katchman AN, Mcgroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K currents. J Pharmacol Exp Ther. 2002;303:688-94.
3. Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77(2):392-7.
4. Bailie DS, Inoue H, Kaseda S, et al. Magnesium suppression of early after depolarizations and ventricular tachyarrhythmias induced by cesium in dogs. Circulation. 1988;77(6):1395-402.
5. Choy AM, Lang C, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96(7):2149-54.
6. Krantz MJ, Lewkowiez L, Hays H, et al. Torsades de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137(6):501-4.